Myriad Genetics (MYGN) Q2 Revenue Up 6%

Myriad Genetics (NASDAQ:MYGN), a molecular diagnostics and precision medicine company known for genetic testing in oncology, women’s health, and mental health, released its Q2 2025 earnings on August 5, 2025. The most important news was that revenue (GAAP) reached $213.1 million, beating the consensus GAAP estimate of $201.9 million. Adjusted earnings per share (EPS, Non-GAAP) came in at $0.05, also above analyst expectations of $(0.01) non-GAAP EPS. However, the headline figures were overshadowed by a major impairment charge of $316.7 million (GAAP), resulting in a GAAP net loss. Overall, the quarter marked a modest return to revenue growth, as GAAP revenue grew 1% year-over-year. Gross margin of 71.2% increased over 160 basis points year-over-year, and optimism for new product lines, In Q1 2025, revenue declined by 3% year-over-year, but excluding headwinds of $16 million, revenue increased 5% year-over-year. In Q2 2025, revenue increased by 1% year-over-year, and excluding headwinds of $9.5 million, revenue increased 5% year-over-year. Cash flow used in operations was $16.3 million in Q1 2025 and $13.6 million in Q2 2025. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Myriad Genetics specializes in molecular diagnostic testing, offering genetic screening and analysis to help inform medical decisions in cancer, women’s health, and mental health. Its products are used by healthcare providers to identify hereditary risks, guide treatment options, and predict patient response to therapies. The company’s revenue model relies heavily on test volume, payer reimbursement, and ongoing innovation in test development.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool